STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials

An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.

STAT News·October 23, 2026·1 min read

or via:

An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.

This content is a summary of the original article published by STAT News. Visit the source for the full version.

Original Source

STAT News

Sponsored Listings